Cannabis Science Inc (OTCMKTS:CBIS), which happens to be a leading U.S based Cannabis production company was happy to make the announcement on its first move to establish pre-designed greenhouses with reporting and full tracking protocols. They will come in as important assets to the company’s operations in Nevada and California.
Dr. Allen Herman, who is the CMO wishes for the company to establish great control over its own supply chain since that seems to be the best way towards boosting efficiency. It will be towards the best interest of the company if it will manage to cut down on time as well as the associated costs towards coming up with the processed products. The company may soon be unveiling a number of observational studies to scrutinize a wide range of cannabinoid combinations meant to treat critical ailments.
The market leader hopes that soon it will grow a wide array of cannabinoid combinations, which it intends to use for its testing and formulations as well. Each particular formulation will aim at facing out a specific ailment. Again, each formulation will seek to work following a particular mode of delivery and should at the same time bear potency to push for maximum positive results when it comes to the patient’s usage.
CBIS, Inc. has in the recent past obtained large volumes of emails and all of them are about different people making inquiries in regards to the timing of clinical research as well as the nature of treatment options availability. The inquiries at the forefront include those about pain management, cancer, COPD and the peripheral neuropathies. The company’s in-house database has all the forwarded inquiries and has put plans in place that will ensure all those inquiries have been attended to.
The provider also looks forward to developing protocols for its international consortium of US, European and South African research bodies as well as universities. This consortium will device research protocols for the clinical tests for a number of critical clinical ailments and that of the animal studies. They will be running concurrently and that will save a lot of time.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: